Objective: Catecholamines have been the mainstay of pharmacological treatment of cardiogenic shock (CS). Recently, use of epinephrine has been associated with detrimental outcomes. In the present study we aimed to evalu‑ ate the association between epinephrine use and short‑ term mortality in all‑ cause CS patients. Design: We performed a meta‑ analysis of individual data with prespecified inclusion criteria: (1) patients in non ‑ sur‑ gical CS treated with inotropes and/or vasopressors and (2) at least 15% of patients treated with epinephrine adminis‑ trated alone or in association with other inotropes/vasopressors. The primary outcome was short‑ term mortality. Measurements and results: Fourteen published cohorts and two unpublished data sets were included. We stud‑ ied 2583 patients. Across all cohorts of patients, the incidence of epinephrine use was 37% (17–76%) and short‑ term mortality rate was 49% (21–69%). A positive correlation was found between percentages of epinephrine use and short‑ term mortality in the CS cohort. The risk of death was higher in epinephrine‑ treated CS patients (OR [CI] = 3.3 [2.8–3.9]) compared to patients treated with other drug regimens. Adjusted mortality risk remained striking in epinephrine‑ treated patients (n = 1227) (adjusted OR = 4.7 [3.4–6.4]). After propensity score
Intensive Care Medicine – Springer Journals
Published: Jun 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera